Microtransplantation Outcomes for Older AML Patients in a Single-Center Study

Table 2_Microtransplantation improves the outcome of older patients with newly diagnosed acute myeloid leukemia: a single-center study with long-term follow-up.xls contains clinical trial data from a single-center study. The study involved 29 patients aged 60 and over, treated between April 2008 and June 2021, with a median follow-up of 148.5 months. The dataset, authored by Juan Liu and shared under a CC-BY-4.0 license, includes endpoints such as complete remission, overall survival, and leukemia-free survival.

Use Cases

• Analyze the association between patient age groups (60-70 vs. >70) and clinical outcomes like overall survival based on the study results.
• Model the relationship between the number of treatment courses (>3) and patient survival metrics mentioned in the description.
• Investigate competing risks of relapse and non-relapse mortality using the cumulative incidence data provided.
• Perform transcriptomic data integration for a subset of long-term survivors based on the described gene expression profiles.

Strengths

• Long-term follow-up with a median of 148.5 months (over 12 years).
• Includes detailed clinical endpoints for 29 patients, such as complete remission (86.2%) and overall survival (median 20.00 months).
• Data covers a specific treatment protocol (Microtransplantation) for a well-defined patient cohort (newly diagnosed AML, age ≥60).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study with 29 patients, which may limit generalizability.

Provenance

Source

Juan Liu via figshare

Collection Method

Single-center clinical study data collection.

Time Range

Patient treatment from April 2008 to June 2021, with follow-up.

Freshness

Last updated 2026-03-18 07:39:49; freshness should be verified.

Geography

null